CooperCompanies Launches Strategic Review and Names New Board Chair
CooperCompanies initiates strategic review exploring partnerships and divestitures while appointing Colleen Jay as new board chair. Q4 revenue up 5% to $1.07B.
/ 463 items
#Healthcare↓
Praxis Precision Medicines Achieves Key Milestones in Neurological Treatments
Praxis Precision Medicines announces FDA alignment for essential tremor drug and positive results for epilepsy treatment, marking major progress in neurological disorder therapies.
FDA Clears Vanda's Tradipitant for Motion Sickness Studies
The FDA has lifted a study restriction on Vanda Pharmaceuticals' Tradipitant, potentially making it the first new motion sickness drug in decades.
Denali and Royalty Pharma Strike $275M Deal for Hunter Syndrome Treatment
Denali Therapeutics secures $275 million from Royalty Pharma for tividenofusp alfa, a promising therapy for Hunter syndrome awaiting FDA approval in April 2026.
FDA Shifts to Single Pivotal Trial Requirement for Drug Approvals
FDA plans to require only one pivotal trial for drug approvals instead of two, potentially accelerating development timelines while raising safety and efficacy concerns.
Stifel Begins Coverage of Tango Therapeutics with Bullish Outlook
Stifel initiates coverage of Tango Therapeutics with a Buy rating and $15 target, citing strong potential for its PRMT5 inhibitor vopimetostat and forecasting $1.2B in peak global revenue by 2035.